Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02151253 · ClinicalTrials.gov registry record · Phase 2
Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT02151253 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 81 participants.
The verdict
NCT02151253, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate armodafinil as a wakefulness-promoting therapy as a means of improving residual daytime sleepiness in patients with treated nocturia.
Interventions
- DRUG Placebo
- DRUG Armodafinil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2011-05 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02151253
The ClinicalTrials.gov registry entry for NCT02151253 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02151253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02151253 about?
NCT02151253 is a clinical study titled "Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia". The objective of the study is to evaluate armodafinil as a wakefulness-promoting therapy as a means of improving residual daytime sleepiness in patients with treated nocturia.
What is the current status of trial NCT02151253?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2011-05. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02151253?
The interventions under investigation include: Placebo (DRUG), Armodafinil (DRUG).
Who is sponsoring clinical trial NCT02151253?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.